胸腺新辅助化疗治疗癌症非小细胞肺癌的疗效观察

中国基层医药 Pub Date : 2020-04-01 DOI:10.3760/CMA.J.ISSN.1008-6706.2020.07.026

Linjian Wang

{"title":"胸腺新辅助化疗治疗癌症非小细胞肺癌的疗效观察","authors":"Linjian Wang","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.07.026","DOIUrl":null,"url":null,"abstract":"目的 \n观察胸腺法新联合化疗治疗非小细胞肺癌的临床效果及其对患者免疫功能的影响。 \n \n \n方法 \n选取新野县人民医院2017年1月至2019年1月收治的非小细胞肺癌患者58例，采用随机数字表法分成两组，每组29例。对照组采用紫杉醇、卡铂方案化疗，观察组采用紫杉醇、卡铂方案化疗联合胸腺法新治疗。观察两组临床疗效及免疫功能(CD4＋、CD8＋、CD4＋/CD8＋)的变化。 \n \n \n结果 \n观察组总有效率为93.1%(27/29)，高于对照组的65.5%(19/29)，差异有统计学意义(χ2＝5.874，P<0.05)。治疗后，观察组CD4＋、CD8＋、CD4＋/CD8＋分别为(52.3±1.6)%、(20.5±1.0)%、(2.6±0.5)，均高于对照组的(44.6±1.7)%、(17.6±1.1)%、(2.3±0.4)，差异均有统计学意义(t＝17.813、10.506、4.515，均P<0.05)。 \n \n \n结论 \n胸腺法新联合紫杉醇、卡铂方案化疗可显著提高非小细胞肺癌患者的治疗效果，改善患者的免疫功能。","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Observation on the effect of thymus neoadjuvant chemotherapy for non-small cell lung cancer\",\"authors\":\"Linjian Wang\",\"doi\":\"10.3760/CMA.J.ISSN.1008-6706.2020.07.026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"目的 \\n观察胸腺法新联合化疗治疗非小细胞肺癌的临床效果及其对患者免疫功能的影响。 \\n \\n \\n方法 \\n选取新野县人民医院2017年1月至2019年1月收治的非小细胞肺癌患者58例，采用随机数字表法分成两组，每组29例。对照组采用紫杉醇、卡铂方案化疗，观察组采用紫杉醇、卡铂方案化疗联合胸腺法新治疗。观察两组临床疗效及免疫功能(CD4＋、CD8＋、CD4＋/CD8＋)的变化。 \\n \\n \\n结果 \\n观察组总有效率为93.1%(27/29)，高于对照组的65.5%(19/29)，差异有统计学意义(χ2＝5.874，P<0.05)。治疗后，观察组CD4＋、CD8＋、CD4＋/CD8＋分别为(52.3±1.6)%、(20.5±1.0)%、(2.6±0.5)，均高于对照组的(44.6±1.7)%、(17.6±1.1)%、(2.3±0.4)，差异均有统计学意义(t＝17.813、10.506、4.515，均P<0.05)。 \\n \\n \\n结论 \\n胸腺法新联合紫杉醇、卡铂方案化疗可显著提高非小细胞肺癌患者的治疗效果，改善患者的免疫功能。\",\"PeriodicalId\":10226,\"journal\":{\"name\":\"中国基层医药\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国基层医药\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.07.026\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.07.026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Objective: To observe the clinical efficacy of thymic neoadjuvant chemotherapy in the treatment of non-small cell lung cancer and its impact on the immune function of patients. Method: 58 patients with non-small cell lung cancer admitted to Xinye County People's Hospital from January 2017 to January 2019 were selected and randomly divided into two groups using a random number table method, with 29 patients in each group. The control group received chemotherapy with paclitaxel and carboplatin regimens, while the observation group received chemotherapy with paclitaxel and carboplatin regimens combined with thymic neotherapy. Observe the clinical efficacy and changes in immune function (CD4+, CD8+, CD4+/CD8+) of two groups. The total effective rate of the observation group was 93.1% (27/29), which was higher than 65.5% (19/29) of the control group, and the difference was statistically significant（ χ 2=5.874, P<0.05). After treatment, the levels of CD4+, CD8+, CD4+/CD8+in the observation group were (52.3 ± 1.6)%, (20.5 ± 1.0)%, and (2.6 ± 0.5), respectively, which were higher than those in the control group (44.6 ± 1.7)%, (17.6 ± 1.1)%, and (2.3 ± 0.4). The differences were statistically significant (t=17.813, 10.506, and 4.515, all P<0.05). Conclusion: Thymic therapy combined with paclitaxel and carboplatin chemotherapy can significantly improve the therapeutic effect and immune function of non-small cell lung cancer patients.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Observation on the effect of thymus neoadjuvant chemotherapy for non-small cell lung cancer

目的观察胸腺法新联合化疗治疗非小细胞肺癌的临床效果及其对患者免疫功能的影响。方法选取新野县人民医院2017年1月至2019年1月收治的非小细胞肺癌患者58例，采用随机数字表法分成两组，每组29例。对照组采用紫杉醇、卡铂方案化疗，观察组采用紫杉醇、卡铂方案化疗联合胸腺法新治疗。观察两组临床疗效及免疫功能(CD4＋、CD8＋、CD4＋/CD8＋)的变化。结果观察组总有效率为93.1%(27/29)，高于对照组的65.5%(19/29)，差异有统计学意义(χ2＝5.874，P<0.05)。治疗后，观察组CD4＋、CD8＋、CD4＋/CD8＋分别为(52.3±1.6)%、(20.5±1.0)%、(2.6±0.5)，均高于对照组的(44.6±1.7)%、(17.6±1.1)%、(2.3±0.4)，差异均有统计学意义(t＝17.813、10.506、4.515，均P<0.05)。结论胸腺法新联合紫杉醇、卡铂方案化疗可显著提高非小细胞肺癌患者的治疗效果，改善患者的免疫功能。

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国基层医药

CiteScore

0.10

自引率

0.00%

发文量

32251

期刊介绍： Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.